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Background: This study investigates the impact of an automated image guided patient setup correction on the
dose distribution for ten patients with in-field IMRT re-irradiation of vertebral metastases.
Methods: 10 patients with spinal column metastases who had previously been treated with 3D-conformal radiotherapy
(3D-CRT) were simulated to have an in-field recurrence. IMRT plans were generated for treatment of the vertebrae
sparing the spinal cord. The dose distributions were compared for a patient setup based on skin marks only and a Cone
Beam CT (CBCT) based setup with translational and rotational couch corrections using an automatic robotic image
guided couch top (Elekta - HexaPOD™ IGuide® - system). The biological equivalent dose (BED) was calculated to evaluate
and rank the effects of the automatic setup correction for the dose distribution of CTV and spinal cord.
Results: The mean absolute value (± standard deviation) over all patients and fractions of the translational error is 6.1 mm
(±4 mm) and 2.7° (±1.1 mm) for the rotational error. The dose coverage of the 95% isodose for the CTV is considerable
decreased for the uncorrected table setup. This is associated with an increasing of the spinal cord dose above the
tolerance dose.
Conclusions: An automatic image guided table correction ensures the delivery of accurate dose distribution and
reduces the risk of radiation induced myelopathy.
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The spinal column belongs to the most common sites for
cancer cells to metastasize [1]. These metastases are often
associated with spinal cord compression resulting in sig-
nificant pain and neurological deficits [2]. Radiotherapy
has shown to be a proven method to relieve pain and pre-
vent complications [3-5]. However, a considerable percent-
age of patients develop a metastatic recurrence within the
initially irradiated region. For these patients in-field re-
irradiation can be an option [6,7]. Though the risk of myel-
opathy has to be minimized by assuring that the summed
spinal cord dose does not exceed a certain tolerance value
[8-11]. Modern radiation techniques like cyberknife treat-
ment [12], stereotactic body radiotherapy (SBRT) [13,14],* Correspondence: christian.groeger@klinik.uni-regensburg.de
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reproduction in any medium, provided the orintensity modulated radiotherapy (IMRT) [15-18] or volu-
metric modulated arc therapy (VMAT) [19,20] reduce the
dose to the spinal cord and allow an effective treatment of
the vertebra bone metastasis at the same time. This is
accomplished by creating a steep dose gradient between
tumor tissue and organ at risk, so that in case of spinal
column metastases the radiation sensible spinal cord can
be protected during the treatment planning process. The
application of such highly locally resolved treatment tech-
niques tighten the problem of a locally very precise treat-
ment delivery to avoid severe damage to the patient. A
precise dose delivery including a very accurate patient
setup is essential for the positive outcome of the treatment
avoiding tumor underdosing and overdosing of critical
structures. Image guided (IG) treatment techniques like
cone beam computed tomography (CBCT) in combin-
ation with an automated patient setup correction systemLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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setup [18,21,22].
This study investigates the impact of an automated patient
setup correction by the Elekta XVI-IGuide®-HexaPOD™
system on the dose distribution for ten patients simulating
an in-field re-irradiation of vertebral metastases using
IG-IMRT techniques. The dose distribution of patient
setup using only skin marks is compared with the dose
distribution after an automated setup correction.
Methods
Equipment
Treatment planning was performed with Oncentra® Exter-
nal Beam v4.1. Patients were irradiated with a Synergy® S
(Elekta Ltd, Crawley, UK) linear accelerator with Beam
Modulator™ head (21 cm × 16 cm max. field, 4 mm leaf
width at isocenter). The Synergy® S Platform is equipped
with a XVI Cone Beam CT (CBCT) with a flat panel de-
tector. For precise patient setup the patient couch (Precise
Table, movable in 3 translation directions) is additionally
upgraded with a robotic HexaPOD™ Couch Top (Medical
Intelligence, Schwabmünchen, Germany), which allows
translations and rotations in six independent degrees of
freedom. This system uses an infrared camera system
(IGuide®, Elekta) for automated patient setup correction.
Patients
10 patients with spinal column metastases who had pre-
viously been treated with 3D-CRT (1st treatment course)
were selected from our treatment database for this retro-
spective study. The irradiated region includes 1–5 thor-
acic vertebrae (including spinal cord). For this study it
was assumed that these patients have an in-field recur-
rence and the whole vertebra region (including the
spinal canal) was pretreated with a dose of 10 × 3 Gy in
the first course. For the second course the CTV con-
sisted of one to five whole vertebra including the verte-
bral body, the vertebral arch, the transverse processes
and the spinous process. The spinal canal was excluded
from the CTV. The PTV was defined as CTV + 3 mm
in each direction excluding the spinal canal from this
expansion. The biological equivalent dose BED was
calculated according to the formula BED = n ∙ d ∙ (1 + d/
(α/β)) [8], where n is the number of fractions, d is the
dose per fraction and α and β are the linear and quad-
ratic coefficients of linear-quadratic cell killing probabil-
ity. According to the literature the α/β value for the
spinal cord tissue was assumed to be 2 Gy [8]. Therefore
the BED of the first radiation course of 10 × 3 Gy is
BED1 = 75 Gy2. Based on the risk score model of Nieder
et al. [8,9], the risk of radio myelopathy appears small
after a summed BED (BEDtot) < 120 Gy2 when the inter-
val is not shorter than 6 months and the dose of each
course is < 98 Gy2. Due to the fact that the BED isadditive the BED of the spinal cord tissue of the second
treatment course should not exceed 45 Gy2 (BED2)
[4,23]. The dose prescription for the second course was
6 × 4 Gy (BED2 = 72 Gy2, BEDtot = 147 Gy2). In order to
minimize the risk of radio myelophaty only a dose of 6 ×
3 Gy (75% of the prescribed dose, BED2 (spinal cord) =
45 Gy2) is allowed at the spinal cord for the 2nd course
(the calculation is described in [15]).
Treatment planning
IMRT plans were generated for each patient allowing
coverage of the target region while sparing the spinal
cord. The following objectives for planning were applied:
– PTV: The 95% isodose covering the outer PTV (a
dose deficit in the spinal cord direction is allowed to
establish an dose gradient and spare the spinal cord)
– Spinal Cord: D0.1ccm < 18 Gy, i.e. the doses exceeding
18 Gy is delivered to a volume smaller than 0.1 ccm
to avoid radio myelopathy. 18 Gy equates to 75% of
the prescribed dose.
– The region of the dose gradient from PTV to spinal
cord should be minimized.
CT-slice thickness and dose grid were set to 2 mm. All
plans were optimized using collapsed cone dose calcula-
tion algorithm with 9 isotropically distributed beam direc-
tions. Max. 80 segments and “step and shoot” technique
were used. The prescribed dose is normalized to the aver-
age of a structure which is equivalent to the PTV minus
3 mm margin around the spinal cord. The isocenter was
set to the middle of the spinal cord.
Patient setup errors
Before the first treatment the correct position of the iso-
center was checked at the simulator by taking sagittal
and coronal x-ray images. Skin marks were placed to
localize the isocenter. During the 1st treatment course
CBCTs in treatment position were acquired for each pa-
tient: Patients are positioned according to the skin
marks and a CBCT was acquired and registered with the
planning CT by automatic matching the outlines of the
bones in both CT data sets. The setup error values were
automatically calculated from the software and trans-
ferred to the HexaPOD™ system for an automatic table
shift. New skin markers for the isocenter were placed if
a table correction was performed in the same direction
at two successive days. The first six setup error values of
the 1st treatment course were taken as hypothetical
setup errors for this study. A comparison was performed
between the dose distribution calculated for the uncor-
rected CT data set and for the corrected CT dataset
which is identical to the planning CT. The uncorrected
CT data set was created by shifting and rotating the
Table 1 Risk evaluation
Absolute error 3D vector Max dose D01ccm BED (Gy2) Risk factor
Translation (mm) Rotation (°) % Gy Max dose Total
Patient 1 10.2 3.3 86.7 20.8 56.8 131.8 2
Patient 2 5.6 3.3 85.3 20.5 55.4 130.4 2
Patient 3 4.2 2.8 78.6 18.9 48.5 123.5 1
Patient 4 10.0 3.7 94.8 22.8 65.9 140.9 3
Patient 5 6.1 3.1 88.4 21.2 58.7 133.7 2
Patient 6 5.4 3.0 94.2 22.6 65.2 140.2 3
Patient 7 5.9 2.1 82.9 19.9 52.9 127.9 1
Patient 8 2.8 2.1 78.1 18.7 48.0 123.0 1
Patient 9 4.3 2.0 79.9 19.2 49.8 124.8 1
Patient 10 6.2 1.7 82.2 19.7 52.2 127.2 1
mean value 6.1 2.7
Absolute error, maximum dose, BED and risk factor for each patient in case HexaPOD™ correction is not performed.
Table 2 Evaluated dose parameters
Corrected Uncorrected t-test
Mean SD Mean SD p value
CTV V95% 86.6 1.9 81.6 3.8 0.0036
DAVG 98.9 0.3 98.4 1.2 0.3284
D99% 79.6 2 78 1.5 0.0860
D01% 104.8 0.7 104.3 1.4 0.3413
H 0.26 0.03 0.27 0.02 0.3383
PTV V95% 89.8 1.4 79.4 6.3 0.0007
DAVG 99.6 0.2 97.7 1.2 0.0010
D99% 80.4 1.7 76.4 3.5 0.0091
D01% 105.3 0.7 103.8 1.4 0.0148
H 0.25 0.02 0.28 0.03 0.0329
SC (D0.1ccm)% 75.1 0.5 85.1 5.7 0.0005
(D0.1ccm)Gy 18.0 0.1 20.4 1.4 0.0005
D99% 37.2 14.6 38.3 13.6 0.8731
DAVG 63.3 1.7 68.9 3.5 0.0008
(V75%)ccm 0.1 0.0 3.7 3.6 0.0160
Comparison of evaluated dose values with and without HexaPOD™ setup
correction. A p-value of less than 0.05 is assumed to be significant.
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ware according to the setup error values above for each
fraction. Afterwards, the original treatment plan is calcu-
lated on this new CT. The dose distribution of each frac-
tion is summed up to a total dose, which represents the
dose distribution for the patient without performing a
XVI based setup correction. The translational setup
error values are defined as follows: x axis (left-right),
y axis (cranio-caudal) and z axis (anterior-posterior); and
for the rotational errors: α (pitch, i.e. rotation around
x-axis), β (roll, i.e. rotation around y-axis) and γ (yaw,
i.e. rotation around z-axis).
Dose parameters
The following parameters are evaluated from the DVH
to specify the quality of dose distributions before and
after setup correction with the HexaPOD™ system.
Percentage dose values refer to the prescribed dose
DAVG(PTV) = 24 Gy.
CTV and PTV:
– Dose coverage V95%: Percentage of volume receiving
95% of the prescribed dose
– Average dose DAVG
– Minimum dose D99%: Percentage of prescribed dose
which covers 99% of the volume
– Maximum dose D01%: Percentage of prescribed dose
which covers 1% of the volume
– Homogeneity index: H = (D99%-D01%)/DAVG
Spinal cord (SC):
– Maximum dose D0.1ccm: Percentage of prescribed
dose which covers 0.1 ccm of the volume– Minimum dose D99%: Percentage of prescribed dose
which covers 99% of the volume
– Average dose DAVG(SC)
– V75%(SC) : absolute volume receiving more than
75% of the prescribed dose
Results
Setup error
Absolute values (± standard deviation) of the translational
and rotational setup errors are given in Table 1. The mean
translational errors (± standard deviation) over all patients
Figure 1 Dose distributions for patient 1. Dose distribution (isocentric transversal slice: top and isocentric sagittal slice: bottom) for patient 1
before (right) an after (left) setup correction. Displayed are isodose lines for 50% (12 Gy - blue), 75% (18 Gy - yellow), 95% (22,8 Gy - light green),
100% (24 Gy - dark green) and 105% (25,2 Gy - light red); CTV is marked in purple, PTV in brown red and spinal cord in orange.
Gröger et al. Radiation Oncology 2013, 8:269 Page 4 of 6
http://www.ro-journal.com/content/8/1/269and fractions were 6.1 mm (±4 mm) and 2,7° (±1.1 mm)
for the rotational error.Figure 2 Hot spots inside the spinal canal. Sagittal icocentric
slice for patient 1 with (left) and without (right) CBCT table setup
correction. Hotspots (dose over the allowed tolerance dose of
18 Gy) inside the spinal canal are displayed in red. CTV is marked in
purple and spinal cord in orange.Dose distribution
Table 2 gives a summary of the dose values for the evalu-
ated regions of interest CTV, PTV and spinal cord. The
most obvious differences in the dose distribution of CTV
and PTV can be seen at the parameter V95%. The mean
value is considerably decreased from 86.6% to 81.6% for
CTV and from 89.9% to 79.4% for PTV, respectively if the
table position is not corrected with the HexaPOD™ system.
The highest difference in the CTV is observed for patient
1: 89.6% (corrected) – 71.3% (uncorrected). Figure 1 shows
the dose distribution for patient 1 before (right) and after
(left) setup table correction. The lowest difference is given
for patient 6: 84.3% (corrected) – 83.6% (uncorrected).
The evaluated dose parameters for the spinal cord are
listed in Table 2. The mean maximal dose D0.1ccm is signifi-
cantly increased from 75.1% of the prescribed dose
(18.0 Gy) to 85.1% (20.4 Gy). For instance patient 4 obtains
a maximum of 94.8% of the prescribed dose (22.8 Gy) in
case the patient setup is performed by skin marks only andis not corrected with the HexaPOD™ system. This is accom-
panied with an increase of the spinal cord volume which re-
ceives more than 75% of the prescribed dose. The mean
value V75%(SC) grows from 0.1 ccm to 3.7 ccm. Figure 2
shows the hot spot areas inside the spinal canal for
Gröger et al. Radiation Oncology 2013, 8:269 Page 5 of 6
http://www.ro-journal.com/content/8/1/269patient 1 before (right) and after (left) setup table correc-
tion. The converted maximum dose in BED is given in
Table 1 for each patient.Discussion
The low radiation tolerance of spinal cord limits the possi-
bility of irradiation of in-field recurrence of spinal cord
metastases. Nieder et al. [8,9] evaluated published clinical
data of 78 patients who received an in-field re-irradiation
of spinal vertebra metastases. Due to these data they
established a risk score to estimate the probability of
myelopathy after in field re-irradiation based on the
applied total biologically effective dose (BED). The risk
score ranges from 0 (total BED ≤ 120: very low risk) to 9
(total BED > 200: very high risk). Our patients have already
received an exposure dose of BED = 75 Gy2 during the
first treatment course. According to Nieder et al. a dose of
BED = 120 Gy2 at the spinal cord is considered as limit. In
this study we use IMRT for the second treatment course
to create a steep dose gradient between tumor region and
spinal cord and maintain the limit.Patient setup errors
during the treatment are responsible for deviation be-
tween planned and applied dose distribution. This study
shows the impact of an automated patient setup correc-
tion by the Elekta XVI-IGuide®-HexaPOD™ system to the
dose distribution for ten patients simulating an in-field
re-irradiation of vertebral metastases using IMRT tech-
niques. The dose distribution of patient setup using skin
marks only is compared with the dose distribution after
an automated setup correction. The most sensitive param-
eter in our case is the dose at the spinal cord. The total
BED for a patient setup performed only by skin marks is
given in Table 1: All patients obtain a higher dose than
BED = 120 Gy2 at the spinal cord which is the maximum
dose what was allowed during planning. Therefore a risk
factor of 0 could not be accomplished without CBCT
setup correction. 2 patients received even a dose of BED >
140 Gy2 and a risk factor of 3 with an increased risk of
myelopathy. Apart from the maximum dose at the spinal
cord the absolute volume which receives an increased
dose is also regarded to be important. Therefore the spinal
cord volume V75% was also evaluated. The mean value
increases from 0.1 ccm to 3.7 ccm. Patient 1 shows even
an increase of the volume to 12.5 ccm (see Figure 2). Due
to the requirement of a steep dose gradient a dose
coverage of 100% to PTV or CTV could not be achieved
in the initial planning. Our analysis shows that patient
setup errors have an additional effect on dose coverage of
the PTV and CTV. The dose coverage V95% is consider-
ably decreased from 89.9% to 79.4% (PTV) and 86.6%
to 81.6% (CTV). Further studies have to be performed
to judge the clinical relevance of this additional loss in
dose coverage.Conclusions
This study shows that the method of patient setup substan-
tially affects the geometric accuracy of the dose delivery. A
patient setup using skin marks only exposes the patients to
risks of radiation induced myelopathy. On the other hand
the application of an automatic IG patient setup like the
Elekta - HexaPOD™ IGuide® - system ensures the delivery
of accurate dose distribution and reduces the risk of radi-
ation induced myelopathy in case of in-field re-irradiation
of vertebral metastases.
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